Opendata, web and dolomites

TETHIS-SBS-CTC

TETHIS-SBS-CTC: An innovative diagnostic testing platform to identify and characterize circulating tumour cells (CTCs) in blood samples.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TETHIS-SBS-CTC project word cloud

Explore the words cloud of the TETHIS-SBS-CTC project. It provides you a very rough idea of what is the project "TETHIS-SBS-CTC" about.

diagnostic    conceived    expecting    biology       monitoring    people    biopsy    liquid    once    characterization    detection    cure    perfect    methodology    secure    cells    clinical    70    pilot    realization    nanotechnology    helps    aggression    environment    15    settings    capability    enrichment    posing    blood    standpoint    therapy    adequately    58    discovery    feasibility    immobilize    earlier    cellular    cancer    total    led    sbs    metastatic    gain    diagnostics    preparation    reflection    capture    oncology    alternatives    market    death    commercial    biotech    huge    tethis    million    finalise    time    profits    diagnosed    rate    biosurface    turn    run    circulating    encloses    chance    financial    tumour    platform    marker    worldwide    smart    pharma    finished    drug    validated    culminating    deaths    decades    ctcs    healthcare    causes    driving    accounting    molecular    hire    proteomic    stage    combination    expertise    roi    sectors    creates   

Project "TETHIS-SBS-CTC" data sheet

The following table provides information about the project.

Coordinator
TETHIS SPA 

Organization address
address: VIA DE GRASSI GIOVANNINO 11
city: MILANO
postcode: 20123
website: www.tethis-lab.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.tethis-lab.com/liquid-biopsy/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TETHIS SPA IT (MILANO) coordinator 50˙000.00

Map

 Project objective

Cancer is one of the most important causes of death worldwide, accounting for 8.8 million deaths. The rate of new cases is expected to rise by 70% in the next 2 decades, posing a huge challenge for the healthcare system. If diagnosed early and treated adequately, many cases would have a high chance of cure. This realization is driving the growth in the cancer diagnostics market. The detection and analysis of Circulating Tumour Cells (CTCs) encloses a huge potential for real-time monitoring of cancer cases. CTCs are considered a “diagnostic tumour marker” since they are the reflection of a metastatic aggression. We at TETHIS have developed a new diagnostic platform to characterize CTCs from liquid biopsy (i.e. blood). The combination of our expertise in nanotechnology and strong biology knowledge have led to the development of a Smart BioSurface (SBS) that creates a perfect environment to immobilize CTCs using a total capture approach. Compared to the state-of-the-art alternatives, our methodology does not require pre-enrichment or selection. Having validated this technology for cancer diagnostics at the pilot stage, this project is conceived to finalise the development and market preparation of this technology, culminating in a diagnostic platform for cellular, proteomic and molecular characterization of CTCs. The platform will have key applications, including diagnostics and monitoring in clinical settings, and drug discovery & therapy development in the pharma/biotech sectors. The Phase 1 of this project is dedicated to run a Feasibility Study that helps us evaluate the project from a technical, commercial and financial standpoint. Once the project is finished, we expect our platform to improve the diagnostic capability in the oncology sector, enabling earlier detection and better management. In turn, it will secure the growth for TETHIS, expecting to gain over €10 million in profits, hire 15 new people and reach a ROI of €2.58 from this project after 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TETHIS-SBS-CTC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TETHIS-SBS-CTC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More